Evidence map›Paper›PMID 41092481›Full record

ArticleBlood advances2026

A practical tool for predicting outcomes in essential thrombocythemia: Triple A risk model and beyond.

Özge Sönmez, Esiyla Oyur, İpek Yönal Hindilerden, Fehmi Hindilerden, Mehmet Sönmez, Abdülkadir Karışmaz, Zeynep Atlı, Teoman Soysal, Ahmet Emre Eşkazan

Abstract read
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Özge SönmezDepartment of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University Cerrahpaşa, Istanbul, Turkey.ORCID 0000-0002-7433-4447
Esiyla OyurCerrahpaşa Faculty of Medicine, Istanbul University Cerrahpaşa, Istanbul, Turkey.ORCID 0009-0003-0590-9985
İpek Yönal HindilerdenDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Istanbul University, Istanbul, Turkey.ORCID 0000-0003-3020-850X
Fehmi HindilerdenDivision of Hematology, Department of Internal Medicine, Bakırköy Dr Sadi Konuk Training Hospital, Istanbul Health Science University, Istanbul, Turkey.ORCID 0000-0002-6297-9555
Mehmet SönmezDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.ORCID 0000-0002-2176-4371
Abdülkadir KarışmazDivision of Hematology, Department of Internal Medicine, Istanbul Teaching and Training Hospital, Istanbul, Turkey.ORCID 0000-0002-5556-7501
Zeynep AtlıDepartment of Statistics, Faculty of Science and Letter, Sinop University, Sinop, Turkey.ORCID 0000-0002-2959-0978
Teoman SoysalDivision of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University Cerrahpaşa, Istanbul, Turkey.ORCID 0000-0002-7417-2118
Ahmet Emre EşkazanDivision of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University Cerrahpaşa, Istanbul, Turkey.ORCID 0000-0001-9568-0894

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractThe management of essential thrombocythemia (ET) relies on risk stratification; therefore, easily applicable risk scores with improved prognostic value are in demand. The Triple A risk score is a novel model incorporating age, absolute neutrophil, and absolute lymphocyte counts (AAA model). In this study, we aimed to evaluate the predictive performance of Triple A score in ET for survival and its complications in an independent cohort, in addition to refining the model by incorporating absolute monocyte count and neutrophil-to-lymphocyte ratio (NLR). Demographic, clinical, and laboratory data of 565 patients with ET were retrospectively collected. Based on Triple A score, 250 patients were classified as low risk, 228 as intermediate-1 risk, 37 as intermediate-2 risk, and 50 as high risk. Over a median follow-up of 6 years, 10.3% patients developed thrombosis, 4.4% experienced bleeding, 5.1% had post-ET myelofibrosis, and 10.9% died. There were significant differences in overall survival and thrombosis-free survival across risk groups. Monocytosis (>0.8 × 109/L) was associated with increased mortality and its prevalence increased progressively with higher Triple A scores. Elevated NLR was also linked to a higher risk of mortality, and moreover, NLR-monocyte-age-based risk score demonstrated significant differences in survival risk. Consequently, Triple A score is an easy-to-use and reliable tool for predicting survival and thrombosis in ET. Incorporating monocytosis into Triple A (AAA+A model) may further enhance its prognostic accuracy. NLR also demonstrated prognostic value both independently and as component of NLR-monocyte-age-based model, highlighting its potential as a robust tool for risk stratification.

Indexed as

Thrombocythemia, EssentialAdultAgedAged, 80 and overFemaleHumansLeukocyte CountMaleMiddle AgedMonocytesNeutrophilsPrognosisRetrospective StudiesRisk AssessmentRisk Factors

Identifiers

PMID41092481
PMCPMC12925115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.